What's more, "orphan drugs" are a completely different ball

New Post Public Reply Private Reply Replies (0) Message Board
patientgal Meach #386

What's more, "orphan drugs" are a completely different ball of wax. I will copy and paste what I posted on iHell a long time ago (was removed of course) as it has occurred to me that I have not posted here. The below might shed some light on why I think (hope) BP will be funding trials.

One-eyed assface is being paid well for his bashing. But, by whom? By iHell? To keep the misinformed in a frantic state so they will spend their money to upgrade to level 2 and beyond thereby keeping themselves better informed (NOT!)?

Whatever the case may be, one-eyed, you're a lowlife ball of shite. Eventually you will piss the Gods off enough that you will be knocked back a peg or two. Until then, where is that emoticon with the middle finger when I need it?

(Yes, I know, very lady-like of me, guys). :-)

From Orphanet:

The so-called 'orphan drugs' are intended to treat diseases so rare that sponsors are reluctant to develop them under usual marketing conditions.

The process from the discovery of a new molecule to its marketing is long (10 years in average), expensive (several tens of millions of euros) and very uncertain (among ten molecules tested, only one may have a therapeutic effect). Developing a drug intended to treat a rare disease does not allow the recovery of the capital invested for its research.

Orphan drugs may be defined as :

Drugs that are not developed by the pharmaceutical industry for economic reasons but which respond to public health need.

Actually, the indications of a drug may also be considered as ' orphan ' since a substance may be used in the treatment of a frequent disease but may not have been developed for another, more rare indication.

In fact, three cases may arise :

  • Products intended to treat rare diseases :
    These products are developed to treat patients suffering from very serious diseases for which no treatment, or at least a satisfactory one, has so far been available. These diseases affect only a small proportion of the population (less than one person per 2,000 in Europe), most often at birth or in infancy. The number of rare diseases for which no treatment is currently available is estimated to be between 4,000 and 5,000 world-wide. Twenty-five to 30 million people are reported to be affected by these diseases in Europe.
  • Products withdrawn from the market for economic or therapeutic reasons :
    For example, thalidomide widely much used as a hypnotic drug some years ago and was then withdrawn from the market when its high teratogenic (triggering fetal malformations) risk was discovered. However this drug showed very interesting analgesic proprieties in diseases such as leprosy or lupus erythematosus. They are diseases for which no satisfactory treatment has been available.
  • Products that have not been developed :
    • either because they are derived from a research process that cannot be patented ;
    • or because they concern important markets which are, however, not creditworthy (see the text  Orphan drugs for Third-World countries ).

Patients affected by rare diseases have to be informed about scientific and therapeutic progress. They have the same rights to care as any other patient. In order to stimulate research and development in the sector of orphan drugs, the authorities have implemented incentives for health and biotechnology industries. It started as early as 1983 in the United States with the adoption of the Orphan Drug Act, then in Japan and in Australia in 1993 and 1997. Europe followed in 1999 by implementing a common EU policy on orphan drugs.

RIVULET MEDIA INC. (RIVU) Stock Research Links

RIVU Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 72

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
MTI Adds Aviation Veterans as Acorn Builds MRO Plan

Updated Category News Views 117

Two old hands entering a boardroom can matter more than another glossy growth slogan, especially in aircraft maintenance, where a delayed part can ground an airplane and turn a customer relationship sour in a hurry. MTI Aviation has added Tony DiSimone Sr. and Aviv Tzur to its board, a move announced November 20, 2026, after Acorn Capital Management took a majority...

Continue Reading
ECW Puts $52 Million Behind Learning Through Crisis

Updated Category News Views 66

A reserve fund for a classroom is not glamorous, but it may be the smartest detail in this whole $52 million commitment. Education Cannot Wait has announced support for more than 300,000 children in Lebanon, Myanmar and South Sudan, where war, flooding and displacement have ripped ordinary schooling apart. The money is meant to restore learning, provide catch-up classes...

Continue Reading
Northgate’s Stanton Opening Puts Community Work First

Updated Category News Views 86

A 55,721-square-foot grocery opening can look like ordinary retail churn until you notice where the money and attention are landing. Northgate González Market’s new Stanton location arrives ahead of Thanksgiving, yes, but the more telling detail is the company’s decision to pair a major store launch with 375 jobs and more than $30,000 directed toward families,...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 61

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Great Rail Journeys Bets Bigger on Luxury Rail in 2027

Updated Category News Views 99

A $19,995 vacation is not selling a seat on a train; it is selling relief from planning, crowds and compromise. Great Rail Journeys is leaning hard into that proposition for 2027 with two additions to its premium Landmark Collection: a Europe-heavy Orient Express and Rhône cruise pairing, plus a South Africa itinerary built around safari, Victoria Falls and rail-flavored...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 44

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 25

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 78

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
Why Insurance Must Change as Family Assets Keep Growing

Updated Category News Views 32

A policy bought in the starter-home years can turn stale quietly while everything around it gets bigger, pricier and more complicated. That is the uncomfortable little truth behind Daniel C. DiCocco's discussion in HelloNation: families often treat insurance as a box checked long ago, even as they add property, savings, debt, children and fresh responsibilities. Static...

Continue Reading

Top 5 Most Recently Viewed Articles

Infrastructure Dividend Split Corp. Exciting Class A Updates

Updated Category News Views 208

Infrastructure Dividend Split Corp. Class A Distributions Overview Infrastructure Dividend Split Corp. (TSX:IS) is making headlines with its recent announcement regarding the June 2025 distributions for Class A shareholders. This initiative is a significant opportunity for investors who hold shares in the Fund, and it emphasizes the ongoing commitment to providing value...

Continue Reading
Navigating Market Opportunities with Domino's Pizza Insights

Updated Category News Views 239

Understanding Market Sensitivity and Its Impact In today's financial markets, there’s a heightened sensitivity to news, especially when stock valuations are at all-time highs. With major indices like the S&P 500 reaching unprecedented levels, stocks have become reactive to various news headlines, often regardless of their actual implications on the business. This...

Continue Reading
Noble Corporation plc Reports Strong FY 2024 Financial Results

Updated Category News Views 475

Noble Corporation plc Reports Strong FY 2024 Financial Results Noble Corporation plc (NYSE: NE) has recently reported its outstanding results for the fourth quarter and the entire fiscal year of 2024. The company's financials highlight a remarkable return of over $575 million via dividends and share buybacks, marking a significant milestone in its operational success and...

Continue Reading
Revolutionizing Home Financing: Hard Money Lenders Arizona

Updated Category News Views 171

Revolutionizing Home Financing with Innovative Loans Hard Money Lenders Arizona, a renowned name in alternative lending solutions, has reshaped the landscape of bridge loans, making them more accessible to homebuyers. Under the expert guidance of CEO Michael Iuculano, the firm leverages over 23 years of industry expertise, enabling thousands of clients to successfully...

Continue Reading
Triumph Financial Shifts Stock Listing to NYSE for Growth

Updated Category News Views 105

Triumph Financial Moves to New York Stock Exchange Triumph Financial, Inc. (NASDAQ: TFIN) has made a significant decision to enhance its market presence by transferring the listing and trading of its common and preferred stock to the New York Stock Exchange (NYSE). This strategic move is not just about a change of scenery; it's a calculated step towards unlocking greater...

Continue Reading